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Abstract 
Background: In recent years, considerable success in reducing its incidence has been achieved in Brazil, leading to 
a relative increase in the proportion of cases caused by Plasmodium vivax, considered a harder‑to‑eliminate parasite. 
This study aim is to describe the transmission dynamics and associated risk factors in a rural settlement area in the 
Western Brazilian Amazon.
Methods: A prospective cohort was established in a rural settlement area for 3 years. Follow‑up included continuous 
passive case detection and monthly active case detection for a period of 6 months. Demographic, clinical and trans‑
mission control practices data were collected. Malaria diagnosis was performed through thick blood smear. Univari‑
able and multivariable analyses of factors associated with malaria incidence were performed using negative binomial 
regression models. Factors associated with recurrence of P. vivax and Plasmodium falciparum malaria within 90 days of 
a previous episode were analysed using univariable and multivariable Cox‑Proportional Hazard models.
Results: Malaria prevalence decreased from 7 % at the study beginning to 0.6 % at month 24, with P. vivax predomi‑
nating and P. falciparum disappearing after 1 year of follow‑up. Malaria incidence was significantly higher in the dry 
season [IRR (95 % CI) 1.4 (1.1–1.6); p < 0.001)]. Use of ITN was associated to malaria protection in the localities [IRR 
(95 % CI) 0.7 (0.6–0.8); p = 0.001)]. A recurrent P. vivax episode within 90 days was observed in 29.4 % of individuals 
after an initial diagnosis. A previous P. vivax [IRR (95 % CI) 2.3 (1.3–4.0); p = 0.006)] or mixed P. vivax + P. falciparum [IRR 
(95 % CI) 2.9 (1.5–5.7); p = 0.002)] infections were significantly associated to a vivax malaria episode within 90 days of 
follow‑up.
Conclusions: In an area of P. falciparum and P. vivax co‑endemicity, a virtual disappearance of P. falciparum was 
observed with P. vivax increasing its relative contribution, with a large proportion of recurring episodes. This finding 
reinforces the perception of P. falciparum being more responsive to early diagnosis and treatment and ITN use and 
the contribution of relapsing P. vivax to maintain this species’ transmission. In areas of P. vivax endemicity, antihypno‑
zoite treatment effectiveness assessment in different transmission intensity may be a fundamental activity for malaria 
control and elimination.
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Background
Malaria is a preventable, diagnosable and treatable dis-
ease. With innovation and roll out of interventions 
there are fewer people dying from malaria now than in 
any other historical period. During 2015, there were an 
estimated 214 million cases of malaria and an estimated 
438,000 deaths (range 236,000–635,000) globally [1]. Fol-
lowing declarations at the malaria Forum in 2007 con-
vened by the Bill & Melinda Gates Foundation (BMGF), 
and later endorsed by the World Health Organization 
(WHO), the international community has embraced the 
goal for scaling up malaria control to regional elimina-
tion and the ultimate goal of global eradication. Today, 
there is on-going malaria transmission in 97 countries; 
twenty-six of these countries are in the ‘pre-elimination’, 
‘elimination’ or ‘prevention of re-introduction’ stages and 
four countries have been WHO certified malaria-free [2]. 
Based on reported data, in the Region of the Americas, 
reductions in incidence of >75  % in malaria cases were 
reported in 13 out of 21 countries with ongoing trans-
mission between 2000 and 2012. Although Brazil has 
achieved an important reduction of malaria transmission, 
it still accounts for 41.7 % of malaria in the Americas [3].
After the World Malaria Eradication Campaign, 
implemented in Brazil in the 1960s, the most successful 
achievement was malaria elimination outside the Ama-
zon. Since then, transmission has been almost entirely 
restricted to the Amazon, with periods of epidemics 
occurring in parallel with increasing migration to the 
region, in part enhanced by development projects subsi-
dized by the government, such as building of roads and 
the creation of a tax-free industrial zone in Manaus [4]. 
From 1992 (the Amsterdam Conference) to 2000, Brazil 
has achieved the goal of reducing substantially the per-
centage of Plasmodium falciparum infections and, there-
fore, the number of hospitalizations and deaths [5]. Since 
2000, an expansion in the financing and coverage of the 
National Malaria Control Programme (NMCP) has led to 
a wide-scale reduction in malaria incidence and mortal-
ity, with considerable shrinkage of the malaria transmis-
sion area towards the Western Amazon region, fostering 
the expectations for planning for elimination in the near 
future [6].
In the context of malaria elimination, Plasmodium 
vivax has been receiving increasing attention due to the 
perception of a greater difficulty to achieve its control as 
compared to P. falciparum [7], with estimated 2.48 billion 
people living at risk of infection [8]. Relapses arising from 
hypnozoites in the liver are a common feature of P. vivax 
malaria. These can occur weeks to years after the ini-
tial infection and place further health burdens on those 
affected. Studies from Brazil showed relapse rates rang-
ing from 14 to 40 % [7–9], thus providing an important 
source of reinfection [10, 11] and hampering malaria 
control. Relapse prevention requires chemotherapy with 
primaquine that targets the latent liver stages of P. vivax 
[12].
Detailed community-based data, including age pat-
terns, incidences and seasonality, are needed not only 
for a better understanding of the problem and possibili-
ties of control and elimination, but also to have baseline 
data to substantiate future interventions, such as vector 
control, mass drug administration or eventually vaccines. 
This work aimed to describe the epidemiology of malaria 
in an endemic area in the surrounding areas of Manaus 
(Brazil), in the Western Brazilian Amazon, including the 
risk factors for incidence and recurrent parasitaemia in 
this endemic area.
Methods
Study sites
The Municipality of Careiro is located in the central 
region of the Amazonas State (Western Brazilian Ama-
zon) (03°06′ S; 60°01′ W), 112  km from the capital of 
the state, Manaus. The estimated population in 2010 
was 32,734 people, mainly living in rural areas (71.2 %). 
The main economical activity is related to agriculture 
(cassava, fruits, vegetables, rice, and sugar cane), cat-
tle breeding, fish-farming, and forestry. These activities 
have resulted in a decrease in vegetation cover and habi-
tat fragmentation. The remaining vegetal cover is pri-
marily composed of dense macrothermic ombrophilous 
forest. The climate according to Köppen classification is 
Af (super-humid equatorial), with a mean pluviometric 
precipitations above 2000 mm per annum, average tem-
peratures ranging from 26 to 30° C, and relative humid-
ity between 85 and 90  %. A rainy season occurs from 
November to April, with an average monthly rainfall of 
290 mm in this season and a peak in February (390 mm); 
a dry season occurs from May to October, with an aver-
age monthly rainfall of 110 mm in this season and lowest 
values in September (45 mm). Mean temperature in the 
period values were 27.6 and 26.9 °C in the dry and rainy 
seasons, respectively [13].
Two areas devoted to agriculture were chosen (Panelão 
Community, a rural settlement, and Castanho Sítio, con-
sisting of ranches along the Manaus-Porto Velho road), 
with a total population of 821 persons (census performed 
immediately before the beginning of the study). The two 
areas were established in the 90  s and present a profile 
of relative low migration and similar environmental, 
socio-economical and demographical features. These 
characteristics, linked to the easy access from Manaus, 
determined in selecting these study areas. Official sur-
veillance shows that malaria is moderately transmitted 
in the communities, with notable seasonality, which is 
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characterized by higher transmission intensity in the 
dry season, when temporary breeding sites form on the 
river margins [4]. Before 2004, P. vivax and P. falcipa-
rum presented similar incidence rates in the area; from 
2004 on, P. vivax predominates (Additional file 1: Figure 
S1). Breeding sites for anophelines are common in the 
surrounding areas and Anopheles darlingi is the major 
malaria vector in the communities [14]. The study area is 
presented in Fig. 1.
The study villages were served with community micros-
copists of local malaria diagnosis and treatment units 
(Fig. 1). As a national policy, a blood smear is collected 
for all febrile cases suspicious of malaria and informa-
tion is registered using a standardized malaria surveil-
lance system. Blood slides are read immediately and if the 
slide is positive anti-malarial treatment is provided by the 
health worker to the patient.
Data retrieval
A prospective cohort study was carried out for 
24 months. Before the start of the study (June 2008), the 
whole population of the areas was submitted to a prelimi-
nary census. At this moment the community was sensi-
tized, informed about the study and invited to participate. 
Follow-up of study participants was done through cross-
sectional surveys and passive case detection at the health 
posts for the entire duration of the study. In total the 
team conducted one visit for census and sensitization 
and cross-sectional surveys every 6 months.
During the five cross-sectional surveys a thick blood 
smear was performed for all individuals within the cohort, 
with or without malaria symptoms, through home visiting. 
At this time if one of the individuals in the cohort were not 
found, only a new visit was scheduled. Moreover, new resi-
dents identified during the cross-sectional surveys were 
invited to enter the cohort. The first (August 2008; T0), the 
third (August 2009; T12) and the fifth (August 2010; T24) 
cross-sectional surveys were performed during the dry 
season and the second (February 2009; T6) and the fourth 
(February 2010; T18) during the rainy season.
For malaria patients reported in the study, first-line 
treatment recommended by the Brazilian Ministry of 
Health to P. vivax malaria (chloroquine for 3  days and 
primaquine for 7 days) and for P. falciparum (artemether 
plus lumefantrine for 3  days and primaquine on the 
1 day) were prescribed [12].
Active follow‑up
Visits in the cross-sectional surveys included a clinical 
history, a physical exam and blood sampling. A finger 
prick blood sample (≈200  µL) was collected to prepare 
two blood smears for detection of Plasmodium infection. 
Information was recorded on standardized forms. Blood 
slides were read at the health post within 24 h and both 
symptomatic and asymptomatic patients with a positive 
thick blood smear detected during the cross-sectionals 
were treated by the study team and/or referred to the 
local hospital.
Fig. 1 Area of study, with the houses and malaria clinics location in the two communities
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Passive case detection
For the purpose of this study, blood was collected to pre-
pare two slides from all patients presenting with fever 
or symptoms compatible with malaria, for individuals 
assisted at the diagnosis and treatment units or at the 
home visits. Following the normal routine of the health 
service of the communities, one blood slide was read 
immediately and if the slide was positive anti-malarial 
treatment was provided by the health worker to the 
patient. Information was registered in a CRF by the com-
munity health workers and microscopists. The second 
slide collected was labelled with the study code and taken 
to Manaus, where it was reviewed by two microscopists 
to confirm diagnosis and for parasite density determina-
tion. Malaria surveillance standardized forms included 
demographic data, clinical characteristics of the patient 
and parasitaemia results. These forms were sent to 
Manaus on a monthly basis, where they were entered into 
databases by two independent data clerks in an OpenCli-
nica® online platform.
Malaria diagnosis and definitions
For all study participants, thick blood smears were pre-
pared as recommended by the Walker technique [15] 
and evaluated by a local microscopist. The slides were 
then sent to Manaus and reviewed by an experienced 
microscopist, who confirmed diagnosis. Parasitologi-
cal results were confirmed by RT-PCR [16]. A calibrated 
clinical examination was made in all subjects submitted 
to thick blood smears examination in the health post. 
Data on the presence of fever, headache, chills, myalgia, 
weakness, sweating, abdominal pain, anorexia, nausea, 
cough, diarrhoea, vomiting, nasal flaring (only in chil-
dren <10  years), crackles, wheezing or ronchi, pallor, 
dehydration, oedema and jaundice were recorded. At 
this moment, patients were asked also if they took anti-
malarials in the last 30 days.
Statistical analysis
The incidence rates of Plasmodium-specific malaria were 
calculated by dividing the respective number of episodes 
by the total person-years at risk in the moment, obtain-
ing overall and group-specific rates and respective sur-
vival curves using Kaplan–Meier method. For describing 
the monthly incidence of malaria and positivity rates, all 
slides performed at each calendar month were combined 
to allow the calculation of monthly incidence of cases per 
species and the slide positivity rate, obtained by dividing 
the malaria positive cases by the total of fever cases that 
had a blood slide performed. Confidence intervals were 
obtained using the quadratic approximation to the Pois-
son log likelihood for the log-rate parameter as described 
in the Stata software manual.
Malaria distribution was analysed with a kernel density 
estimator using the spatial analyst tool from ArcGIS 10.1 
(ESRI, California, USA). Incidence of disease per dwelling 
was used as population field. Output cell size and search 
radius were set to 0.00079 and 0.0066, respectively.
Univariate and multivariate analyses of factors associ-
ated with the incidence of malaria (specific and per-spe-
cies) were performed by comparing the parasite-specific 
incidence rates of malaria episodes between groups using 
a negative binomial regression model with robust stand-
ard error to account for clustering by individual. The 
investigation of factors associated with recurrence of P. 
vivax and P. falciparum malaria within 90 days of a pre-
vious episode was analysed using univariable and multi-
variable Cox-Proportional Hazard models, with robust 
standard errors.
Ethics approval
Human surveys were approved by the National Ethics 
Review Committee (protocol number 15197/2008, and 
the Ethics Committee of the Hospital Clínic, Barcelona, 
Spain. Informed consent was obtained from each par-
ticipant. All malaria cases detected in the longitudinal 
or cross-sectional studies were treated according to the 
Brazilian Ministry of Health guidelines. Patients with 
any clinical complication were referred to the Careiro 
Hospital.
Results
Study population
The census performed before the beginning of the study 
(June 2008) showed 821 people living in the study area. 
The first cross-sectional (August 2008; T0) included 631 
people, the second (February 2009; T6) included 592 
people, the third (August 2009; T12) included 615 peo-
ple, the fourth (February 2010; T18) included 650 peo-
ple and the fifth (August 2010; T24) included 511 people 
(Fig. 2). Subjects included were mostly males (57 %). The 
most frequent age groups were 15–35  years old (28  %) 
and 5–15 years old (27 %). Ethnically, people are mostly 
admixed (98.7 %). In relation to education, subjects had 
mostly elementary school (68 %). Farmer/fisher was the 
most common occupation in the area (39  %) (Table  1). 
A total of 3131 episodes of fever were assessed in the 
period, respectively 1839 in year 1, 956 in year 2 and 336 
in year 3.
Malaria burden
Prevalence of malaria was higher at T0 (7.0  %), drop-
ping to 1.5 % at T6. From T0 to T24, malaria prevalence 
presented a decreasing trend, with a point prevalence of 
0.2  % at T24. Plasmodium falciparum infections were 
recorded only at T0 (1  %) and T6 (0.5  %). Plasmodium 
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vivax was responsible by 87.1 % of all infections observed 
in the cross-sectional evaluations (Fig. 3).
In total, 550 malaria episodes were registered in 
the period, 408 in the first year, 120 in the second 
and 22 in the third, yielding rates of 847, 150 and 41 
episodes/1000-person-year, respectively. The num-
ber of episodes per individual in a given year varied 
from one to seven (maximum of three for P. falcipa-
rum), and among individuals presenting vivax malaria 
in the follow-up, 20.4  % had more than one episode. 
In overall, P. vivax malaria incidence decreased from 
22.1 to 7.9  % and P. falciparum malaria incidence 
decreased from 14.1 to 0.6  % in the period. The inci-
dence of recurrent vivax malaria also decreased over 
the study period, from 3.9 % in 2008 to 0.7 % in 2010. 
Among P. falciparum patients, 11.1 % developed more 
than one episode. Figure  4 shows the decreasing pat-
terns of malaria incidence per species over the period. 
Fig. 2 Flow chart of inclusion along the prospective cohort
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As transmission intensity decreased, the proportion of 
febrile cases dropped considerably. In the beginning of 
the study, more than 70 % of febrile cases had positive 
slides, while in the end of the period, slide positivity 
rate was to less than 10 %.
Malaria cases predominated in the groups aged 
between 10 and 60  years-old. This profile was also 
observed also for P. vivax and P. falciparum malaria. A 
proportion of 8.5  % of the malaria cases were recorded 
from children under 5 years of age.
Spatial distribution shows that malaria cases were 
unevenly distributed in the study area, with higher inci-
dences in the Panelão Community, in the major road and 
in three minor sideroads. In the Castanho Sítio Commu-
nity, malaria cases were more sparsely distributed prob-
ably reflecting this area configuration (Fig. 5). Temporally 
it was possible to observe changes in the “hotspots” 
locations, demonstrating the dynamic characteristic of 
transmission in the region.
Malaria control activities
Coverage of malaria control measures is presented in 
Fig. 6. Window screening use increased from 8 % in T0 to 
78 % of the houses in T24. In the beginning of the follow-
up (T0), 188 (70 %) of the houses had been submitted to 
indoor residual spraying (IRS; cypermethrin) in the pre-
ceding 6  months. IRS coverage slightly increased in the 
period, from 54 % of the houses at T18 to 81 % at T6. A 
total of 378 (60 %) of the subjects referred using bed nets 
in the previous night. In the same way, use of bed net 
ranged from 27 % at T6 to 62 % at T12. However, insecti-
cide-treated bed nets started to be used only at the third 
cross-sectional (T12). In general, patients searched for 
health care within <48 h of symptoms (80.2 %). Only 3 % 
of malaria cases were diagnosed after 7 days after symp-
toms had started. Percentage of cases diagnosed within 
48 h of symptoms ranged from 81.5 % at T0 to 97.3 % at 
T24.
Incidence rate and hazard ratios for malaria
The risk of malaria infection was significantly higher in 
the dry season [IRR (95 % CI) 1.4 (1.1–1.6); p < 0.001)] 
and wherever IRS had been used in the last 6  months 
[IRR (95 % CI) 1.4 (1.1–1.8); p = 0.002)]. Use of ITN was 
associated to malaria protection in the localities [IRR 
(95 % CI) 0.7 (0.6–0.8); p = 0.001)]. Gender, age and soci-
oeconomic status were not related to malaria incidence. 
Stratification by malaria species showed similar results 
(Tables  2 and 3). However, ITN use seemed to have a 
more protective effect on P. falciparum malaria [IRR 
(95  % CI) 0.5 (0.3–0.7); p  <  0.001)] in comparison with 
P. vivax malaria [IRR (95 % CI) 0.7 (0.6–0.8); p = 0.001)]. 
Risk factors for recurrent malaria episodes
Proportion of recurrent malaria episodes by P. vivax 
within 90  days of a previous episode was 189/642 
(29.44  %) (Fig.  7). Recurrences were observed mostly 
between the 28 and 365 days after the first vivax malaria 
episode (81.3  %), and particularly in the 121–365  days 
time-interval (32.2  %). Early recurrences (until 27  days) 
were observed in 7.6  %. Late recurrences (≥365  days) 
were observed in 11.1 %.
A previous P. vivax [IRR (95  % CI) 2.3 (1.3–4.0); 
p = 0.006)] or mixed P. vivax + P. falciparum [IRR (95 % 
CI) 2.9 (1.5–5.7); p = 0.002)] infections were significantly 
associated to a vivax malaria episode within 90  days of 
follow-up. Recurrent P. vivax infections were also sig-
nificantly higher in the dry season [IRR (95  % CI) 2.5 
(1.8–3.5); p = 0.001)] (Table 4). Kaplan–Meier estimates 
confirmed a higher risk of recurrences after a history of P. 
Table 1 Basic demographic information of  the total 
of subjects included in the prospective study
a The term admixed was used as the traduction for the Portuguese term “pardo”, 
used officially by the Brazilian Institute of Geography and Statistics (IBGE), 
referring to a wide range of skin colours and backgrounds. They are typically a 
mixture of White Brazilian, Afro‑Brazilian and Native Brazilian
Variable Results (n and  %)
Sex
Male 664 (57.0 %)
Female 502 (43.0 %)
Age (years)
<5 152 (13.0 %)
5–15 309 (26.5 %)
15–35 321 (27.5 %)
35–50 185 (16.0 %)
>50 199 (17.0 %)
Ethnics
White 9 (0.8 %)
Admixeda 1151 (98.7 %)
Black 5 (0.4 %)
Asian 1 (0.1 %)
Education
Illiterate 259 (22.2 %)
Elementary school 792 (68 %)
Middle school 105 (9 %)
Higher school 10 (0.8 %)
Occupation
Farmer/fisher 457 (39.2 %)
Urban employee 26 (2.2 %)
Housewife 81 (6.9 %)
Student 375 (32.2 %)
Retired 40 (3.4 %)
Unemployed 10 (0.9 %)
Other 177 (15.2 %)
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vivax, mixed P. vivax + P. falciparum and P. falciparum 
infections (Fig.  8). Risk of P. vivax recurrence was not 
associated to to bed net use (Additional file 2: Figure S2). 
Discussion
This study was able to comprehensively characterize 
the epidemiology of malaria in an area coendemic for 
P. falciparum and P. vivax, and in a context of a marked 
decrease incidence between the beginning and the end of 
study activities. This confirms P. vivax as a more resilient 
species, with the virtual disappearance of P. falciparum, 
a reducing proportion of malaria-attributed fever and an 
increasing clustering of malaria episodes with reduced 
incidence. While P. falciparum and P. vivax responded 
each for around 50 % of cases in Brazil in 1988 this situa-
tion started changing in the 1990s, leading to the current 
situation in which P. vivax has become the predominant 
species in recent years (only 16.3 % of cases being due to 
P. falciparum) [4, 5, 17]. This shift has been attributed to 
a number of factors, namely the expansion of the diagno-
sis and treatment network, making opportune treatment 
accessible even in remote areas of the Amazon as part of 
Fig. 3 Malaria prevalence by species in the five cross‑sectional surveys performed in the study obtained by active case detection
Fig. 4 Malaria incidence per species (lines) and slide positivity rates trends per calendar month obtained from the passive case detection of fever 
cases during the period of study
Page 8 of 14Vitor‑Silva et al. Malar J  (2016) 15:266 
the universal health system; the use of integrated vector 
management strategies; and, importantly, the support 
from political leaders in periods of epidemics [5].
In Brazil, current methods for vector control are based 
primarily on the use of long-lasting insecticide-treated 
nets (ITN) and indoor residual spraying (IRS), but there 
is no specific and systematic evaluation on the impact 
that these measures have on suppressing anopheline pop-
ulations and reducing levels of malaria parasite transmis-
sion in recent agrarian reform projects in the Amazon 
[14]. In this study, use of ITN but not IRS was associated 
to malaria protection, higher for P. falciparum (~50  %) 
when comparing to P. vivax (~30 %). Plasmodium vivax 
biological features may have contributed to lower vector 
control effectiveness in this group. Additionally, among 
anopheline collections in these communities, there was 
a predominance of mosquitoes in the peri-domiciliary 
environment [14].
Opportune diagnosis and treatment, especially if pro-
vided within 48 h of symptoms onset, is thought to have 
a relatively higher impact on P. falciparum transmission, 
as gametocytes for this species are usually not detected 
at patent levels before 5 days of the onset of symptoms, 
as compared to P. vivax, for which it occurs much ear-
lier [18, 19]. In this study, most patients were diagnosed 
within three days since the beginning of symptoms 
(94.3  %), demonstrating a sensitive and effective case 
detection system, which is likely to have played an impor-
tant part on the striking reduction of cases observed 
in the period. After malaria diagnosis, treatment was 
immediately prescribed and given free of charge for all 
patients following the recommendations of the Brazilian 
Fig. 5 Spatial and temporal variation of malaria incidence in the study area
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official guidelines, including systematically a course of 
primaquine 0.5  mg/kg/day for 7  days for vivax malaria 
[12]. Unfortunately, treatment was not supervised, but 
patients were followed by an active surveillance of febrile 
cases, further suggesting a good compliance. Timely 
diagnosis and treatment, in parallel with and increase in 
the coverage of malaria vector control measures are sug-
gested to be responsable by the successful reduction in 
malaria incidence.
Besides the later gametocytemia, hypnozoites responsi-
ble for the occurrence of relapses are also believed to be 
an important specific feature of P. vivax that contributes 
to this species burden and less notable responsiveness 
to the usual control measures [18]. This is more difficult 
to measure as recurring episodes can arise from new 
infections, recrudescence or relapses and there are no 
tools that can reliably discriminate between these condi-
tions impairing more robust conclusions. In the lack of 
a design and tools specifically able to measure relapses, 
we have relied on the evaluation of recurrences to esti-
mate the contribution of relapses to the burden of disease 
in the area. Although with marked variation, there was a 
trend towards greater contribution of recurring episodes 
to the total burden of P. vivax with reducing number of 
cases, which in some months accounted for up to 50  % 
of episodes, irrespective of bed net use and routine pri-
maquine prescription. It has been shown through elegant 
investigations that relapses may account for up to 80 % of 
vivax malaria episodes in Papua New Guinea [20], where 
primaquine is not routinely administered, a feature that 
was also observed in other places [21, 22]. Our results 
suggest a high likelihood of relapses contributing to the 
burden of disease and would be in overall accordance 
to the expected interval for its occurrence in the region 
[23]. Our analyses demonstrated that having experienced 
a P. vivax episode (mono or mixed-infection) implied a 
considerable higher risk of presenting a new P. vivax 
clinical episode. Interestingly, for the specific analyses of 
recurrence, bed net use was not associated with protec-
tion, what would be consistent with the suggestion of a 
significant proportion being caused by relapses.
Interestingly, individuals were significantly more likely 
to have recurrent P. vivax infection after a monoinfec-
tion due to P. falciparum, in agreement with previous 
Fig. 6 Operational measures for malaria control coverage in the study area over the period of study
Page 10 of 14Vitor‑Silva et al. Malar J  (2016) 15:266 
observations from Thailand [24]. The patients evaluated 
in Thailand and in our work did not receive hypnozoi-
tocidal therapy for falciparum malaria and, if hypnozo-
ites are present, relapse may occur [25]. One potential 
explanation for this phenomenon is that P. falciparum 
infection, especially in high density, is a proxy marker 
of malaria naivety and hence poor immunity to both P. 
falciparum and P. vivax infections. If this is true, relapses 
due to P. vivax hypnozoites acquired at or around the 
same time as the index P. falciparum infection would 
have a greater chance of reaching patency [24]. Histori-
cal records suggest that systemic parasitic and bacterial 
infections, but not viral infections, can activate P. vivax 
hypnozoites [26].
In non-endemic areas in Brazil, inadequate primaquine 
dosing was found to be associated with P. vivax malaria 
relapses [8, 9]. Unfortunately, patients adherence to anti-
malarial treatment was not measured in the area nor per-
formed specific pharmacological studies [27], as well as 
pharmacogenetic mutations cannot be discarded, such 
as CYP2D6, altering primaquine metabolism [28], fac-
tors that are well-known to alter the effectiveness of 
anti-relapse treatment. One hypothesis is that with a 
reduction of transmission intensity relapses may contrib-
ute to a relatively higher burden of disease, requiring the 
development of specifically-tailored strategies in similar 
scenarios.
In the cross-sectional evaluations, a low frequency 
of fever (22.7 % in T0 to 0 % at T12, T18 and T24) was 
observed among individuals with patent Plasmodium 
infection. In a different rural Amazon location, research-
ers have reported that conventional microscopy missed 
54 % of Plasmodium carriers, indicating a large propor-
tion of low-density infections in low transmission areas 
[29]. These findings suggest that apparently healthy car-
riers of patent parasitaemias are not detected by the rou-
tine health system activities and may have an important 
participation to the infectious reservoir contributing 
to maintain malaria transmission in this setting. Unfor-
tunately, an important limitation of this study is not to 
test this population by PCR and the probable number of 
asymptomatic patients carrying Plasmodium in the area 
is likely to be considerably higher than the reported here. 
Positive microscopy in asymptomatic Plasmodium car-
riers was observed previously in the Brazilian Amazon 
[30–33].
One important finding of this study is that the reduc-
ing incidence of malaria was accompanied by a dramatic 
decrease on the overall incidence of acute fever episodes 
of 80  % from the first to the third year of follow-up. 
Table 2 Incidence rate and hazard ratios for Plasmodium vivax episodes according to exposure status
N episodes Person‑years 
of follow‑up
Rate (episodes/ 
100‑PY) (95 % CI)
Univariable IRR 
(95 % CI)
P value Multivariable IRR 
(95 % CI)
P value
Gender
Female 279 802 34.8 (31.0–39.1) 1 0.151 1 0.204
Male 377 998 37.8 (34.2–41.8) 1.2 (0.9–1.5) 1.2 (0.9–1.5)
Age (years)
0–10 194 451 43.0 (37.3–49.5) 1 1
10–20 143 436 32.8 (27.8–38.6) 0.7 (0.6–1.0) 0.059 0.7 (0.5–0.9) 0.038
20–40 163 429 38.0 (32.6–44.3) 0.9 (0.7–1.3) 0.709 1.0 (0.7–1.3) 0.954
40–60 114 328 34.7 (28.9–41.7) 0.9 (0.6–1.2) 0.461 0.9 (0.6–1.3) 0.524
≥60 42 153 27.3 (20.2–36.9) 0.7 (0.5–1.2) 0.195 0.8 (0.5–1.2) 0.229
Socio‑economic status
Lowest quintile 258 702 36.7 (32.5–41.5) 1.0 (0.8–1.2) 0.798 0.9 (0.7–1.1) 0.422
2nd–4th quintiles 284 707 40.2 (35.8–45.1) 1 1
Highest quintile 114 320 35.6 (29.6–42.7) 1.0 (0.7–1.3) 0.825 0.9 (0.7–1.2)
Season
Rainy 238 750 31.7 (27.9–36.0) 1 0.007 1 <0.001
Dry 418 1049 39.9 (36.2–43.9) 1.2 (1.1–1.5) 1.4 (1.1–1.6)
Use of ITN
No 362 857 42.3 (38.1–46.8) 1 0.199 1 0.001
Yes 294 943 31.1 (27.8–35.0) 0.9 (0.7–1.1) 0.7 (0.6–0.8)
IRS in last 6 months
No 149 530 28.1 (23.9–33.0) 1 0.015 1 0.002
Yes 507 1200 42.3 (38.7–46.1) 1.4 (1.1–1.8) 1.4 (1.1–1.8)
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During the same period, the proportion of malaria-attrib-
uted fever also decreased considerably, from around 
70 % during the high season in the first year of study to 
no higher than 20 % in the third year of follow-up. These 
findings have important implication for the local health 
system and transmission control activities. This figure 
Table 3 Incidence rate and hazard ratios of Plasmodium falciparum episodes according to exposure status
N episodes Person‑years 
of follow‑up
Rate (episodes/ 
100‑PY) (95 % CI)
Univariable IRR 
(95 % CI)
P value Multivariable IRR 
(95 % CI)
P value
Gender
Female 79 802 9.9 (7.9–12.3) 1 1 0.249
Male 118 998 11.8 (9.9–14.2) 1.2 (0.9–1.8) 0.175 1.2 (0.9–1.8)
Age (years)
0–10 51 451 11.3 (8.6–14.9) 1 1
10–20 56 436 12.8 (9.9–16.7) 1.1 (0.6–1.7) 0.847 0.9 (0.6–1.6) 0.833
20–40 49 429 11.4 (8.6–15.1) 1.1 (0.7–1.8) 0.756 1.1 (0.7–1.8) 0.746
40–60 28 328 8.5 (6.0–12.3) 0.8 (0.4–1.4) 0.433 0.8 (0.4–1.5) 0.489
≥60 13 153 8.4 (4.9–14.5) 0.8 (0.4–1.9) 0.648 0.8 (0.4–1.9) 0.621
Socio‑economic status
Lowest quintile 76 702 10.9 (8.6–13.5) 0.9 (0.6–1.3) 0.592 0.9 (0.7–1.4) 0.821
2nd–4th quintiles 92 707 13.0 (10.6–16.0) 1 1
Highest quintile 29 320 9.1 (6.3–13.0) 0.8 (0.5–1.4) 0.415 0.8 (0.5–1.3) 0.397
Season
Rainy 56 750 7.5 (5.7–9.7) 1 <0.001 1 <0.001
Dry 141 1049 13.4 (11.4–15.9) 1.7 (1.3–2.3) 1.7 (1.3–2.3)
Use of ITN
No 138 857 16.1 (13.6–19.0) 1 <0.001 1 <0.001
Yes 59 943 6.3 (4.8–8.1) 0.5 (0.3–0.7) 0.5 (0.3–0.7)
IRS in last 6 months
No 31 530 5.8 (4.1–8.3) 1 0.001 1 <0.001
Yes 166 1200 13.8 (11.9–16.1) 2.1 (1.3–3.4) 1.9 (1.2–3.3)
Fig. 7 Malaria incidence and recurrent parasitaemias in 90 days per month during the period of study
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surely reflects a high proportion of non-diagnosed fevers, 
and the ability of health systems to identify the causes of 
fever is important for both adequate individual case man-
agement and for health surveillance, as demonstrated 
in other areas [34–38]. This could be improved with the 
implementation of a broader and more comprehensive 
primary health care (PHC) in the region. Second, the 
reducing incidence of fever and clinical malaria episode 
Table 4 Hazard ratio of a Plasmodium vivax infection following a previous malaria episode within 90 days of follow-up
Rate P. vivax episode/ 
100‑person‑months
Crude HR  
(95 % CI)
P value Adjusted HR  
(95 % CI)
P value
Initial infection
P. falciparum 5.3 (3.2–8.7) 1 1
P. vivax 11.4 (9.8–12.2) 2.1 (1.2–3.7) 0.009 2.3 (1.3–4.0) 0.006
Mixed Infection 14.2 (9.4–21.6) 2.7 (1.4–5.1) 0.003 2.9 (1.5–5.7) 0.002
Gender
Female 10.5 (8.5–13.0) 1 1 0.983
Male 10.8 (9.0–12.9) 1.0 (0.8–1.3) 0.870 1.0 (0.8–1.3)
Age (years)
0–10 10.0 (7.7–13.0) 1 1
10–20 10.1 (7.5–13.7) 1.0 (0.7–1.6) 0.865 1.1 (0.7–1.5) 0.809
20–40 11.1 (8.5–14.5) 1.1 (0.8–1.6) 0.557 1.2 (0.8–1.8) 0.284
40–60 12.3 (9.0–16.9) 1.2 (0.8–1.8) 0.268 1.3 (0.9–2.0) 0.126
≥60 9.6 (5.4–16.8) 0.9 (0.5–1.7) 0.885 1.0 (0.5–1.7) 0.933
Residence area
Road ranches 8.7 (6.5–11.7) 1 1 0.091
Rural settlement 11.4 (9.8–13.3) 1.3 (0.9–1.8) 0.108 1.3 (1.0–1.9)
Season
Rainy 5.9 (4.4–8.0) 1 1 <0.001
Dry 13.6 (11.7–15.9) 2.4 (1.7–3.3) <0.001 2.5 (1.8–3.5)
Use of ITN
No 11.0 (9.2–13.2) 1 1 0.284
Yes 10.3 (8.3–12.7) 0.9 (0.7–1.2) 0.564 0.9 (0.7–1.1)
Fig. 8 Risk of presenting P. vivax recurrence following a malaria episode by either P. vivax, P. falciparum or mixed infection. a Survival analysis of the 
time for the first malarial episode, showing the time elapsed from a previous non‑malarial fever, P. vivax, P. falciparum or mixed infection until a P. 
vivax clinical episode. b Hazard ratios for presenting a P. vivax clinical episode to last 120 days, for non‑malaria fever, P. vivax, P. falciparum or mixed 
infection
Page 13 of 14Vitor‑Silva et al. Malar J  (2016) 15:266 
make people less likely to seek for care in health facilities 
that only provide malaria diagnosis and treatment as is 
the case of most units in the rural Amazon region, mak-
ing it more difficult to identify and tackle the infectious 
reservoir, what has consensually been agreed as an essen-
tial strategy for the rapid and sustained achievement 
of elimination [39, 40]. Ease of access to PHC has been 
already shown to be an important factor for reducing the 
burden of malaria [41]. Likewise, in a scenario of reduced 
funding, the issue of sustainability of malaria diagno-
sis and control activities is of main importance and may 
only be achieved with integration with other health care 
actions including a well-implemented syndromic surveil-
lance of cases. An evaluation of what occurred in the area 
during the 3 years following the interruption of this study 
demonstrates that there was a resurgence of P. falcipa-
rum and an increase of the incidence of P. vivax (Addi-
tional file 1: Figure S1) and that this was accompanied by 
an increase on the proportion of individuals being diag-
nosed with malaria with more than 48  h of symptoms 
onset (from 6 % in 2010 to 45 % in 2013), what demon-
strates the instability and vulnerability of malaria control 
in the current scenario. After the study was finished, the 
staff of the malaria diagnosis unit decreased, likely con-
tributing for a less effective active search of malaria cases 
and spraying and IRS activities. How to best adapt and 
integrate malaria-specific and other conditions health 
care and control activities is still a major challenge and an 
area for investigation.
Conclusions
Data presented here represent an important contribution 
to the knowledge of the epidemiology of malaria transmis-
sion and vector control in agricultural settlements in the 
Amazon and could be useful to assist on the development 
and implementation of strategies to control and eliminate 
this infection in the region. Eliminating P. vivax is more 
challenging than tackling P. falciparum, and may require 
specific tools and strategies for its containment, especially 
regarding the prevention of relapses [18, 42]. A trend of 
recurring malaria episodes was observed, likely to derive 
from relapses, to increase its relative contribution to the 
burden of disease. Relapsing P. vivax phenotypes may 
be more widespread and more prevalent in the Amazon 
than currently thought. This is an issue that remains to be 
more adequately investigated using enhanced approaches 
that would comprise pragmatic intervention trials and 
molecular methods [20], still to be adequately applied 
in the region. The Brazilian NMCP has launched a plan 
for elimination for P. falciparum in late 2015. Whether 
focusing on this species is a more appropriate strategy 
than attempting to eliminate overall malaria is yet to be 
determined. In order to achieve a rapid and sustained 
elimination of malaria transmission in the region, health 
systems and control strategies will be required to adapt 
to changing epidemiological scenarios through integrated 
and innovative approaches for which design scientists, 
health authorities and communities will have to be work-
ing together towards its achievement.
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